Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina Konopleva

Showing results (1-10 of 642) with videos related to

Pageof 65
Sort By:
Expert Review of Clinical Pharmacology|November 18, 2021
Keeping up with venetoclax for leukemic malignancies: key findings, optimal regimens, and clinical considerationsMaria Siddiqui, Marina Konopleva
Haematologica|February 1, 2021
Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemiaZhihong Zeng, Marina Konopleva
Blood|June 24, 2021
Break the lifeline of AML cellsYoko Tabe, Marina Konopleva
Cancer Drug Resistance (Alhambra, Calif.)|April 17, 2023
Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironmentYoko Tabe, Marina Konopleva
Haematologica|December 2, 2024
Therapy for acute myeloid leukemia in older and unfit adultsMark Forsberg, Marina Konopleva
Clinical Lymphoma, Myeloma & Leukemia|November 25, 2023
SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic MalignanciesMark Forsberg, Marina Konopleva
The Lancet. Oncology|November 10, 2015
Sorafenib and novel multikinase inhibitors in AMLNaval Daver, Marina Konopleva
Expert Opinion on Therapeutic Targets|April 30, 2025
Preclinical targeting of leukemia-initiating cells in the development future biologics for acute myeloid leukemiaJiaxin Dong, Marina Konopleva
Trends in Pharmacological Sciences|April 20, 2024
AML treatment: conventional chemotherapy and emerging novel agentsMark Forsberg, Marina Konopleva
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2017
Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer TherapyNatalia Baran, Marina Konopleva
Pageof 65

Showing results (1-10 of 642) with videos related to

Sort By:
Pageof 65
Expert Review of Clinical Pharmacology|November 18, 2021
Keeping up with venetoclax for leukemic malignancies: key findings, optimal regimens, and clinical considerationsMaria Siddiqui, Marina Konopleva
Haematologica|February 1, 2021
Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemiaZhihong Zeng, Marina Konopleva
Blood|June 24, 2021
Break the lifeline of AML cellsYoko Tabe, Marina Konopleva
Cancer Drug Resistance (Alhambra, Calif.)|April 17, 2023
Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironmentYoko Tabe, Marina Konopleva
Haematologica|December 2, 2024
Therapy for acute myeloid leukemia in older and unfit adultsMark Forsberg, Marina Konopleva
Clinical Lymphoma, Myeloma & Leukemia|November 25, 2023
SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic MalignanciesMark Forsberg, Marina Konopleva
The Lancet. Oncology|November 10, 2015
Sorafenib and novel multikinase inhibitors in AMLNaval Daver, Marina Konopleva
Expert Opinion on Therapeutic Targets|April 30, 2025
Preclinical targeting of leukemia-initiating cells in the development future biologics for acute myeloid leukemiaJiaxin Dong, Marina Konopleva
Trends in Pharmacological Sciences|April 20, 2024
AML treatment: conventional chemotherapy and emerging novel agentsMark Forsberg, Marina Konopleva
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2017
Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer TherapyNatalia Baran, Marina Konopleva
Pageof 65